Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™
February 04, 2025 08:00 ET
|
Spur Therapeutics
Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium
Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
February 03, 2025 08:00 ET
|
Spur Therapeutics
Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
January 23, 2025 08:00 ET
|
Spur Therapeutics
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program
December 03, 2024 07:00 ET
|
Spur Therapeutics
Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program
Spur Therapeutics to Participate in Upcoming Investor Conferences
November 19, 2024 08:00 ET
|
Spur Therapeutics
Spur Therapeutics to Participate in Upcoming Investor Conferences
Spur Therapeutics to Participate in B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit
November 07, 2024 08:00 ET
|
Spur Therapeutics
Spur Therapeutics to Participate in B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)
October 31, 2024 08:00 ET
|
Spur Therapeutics
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)
Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress
October 23, 2024 02:00 ET
|
Spur Therapeutics
Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease
Spur Therapeutics Announces Oral Presentation Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
October 03, 2024 08:00 ET
|
Spur Therapeutics
LONDON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics, formerly Freeline Therapeutics, today announced that it will present updated clinical data from its GALILEO-1 first-in-human clinical...
Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024 08:00 ET
|
Spur Therapeutics
Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference